Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 801–900 of 1,004
Measurement of tumor interstitial volume fraction: Method and implication for drug delivery
Kim, Y. R., Savellano, M. D., Savellano, D. H., Weissleder, R., & Bogdanov, A. A., Jr. (2004) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20182 · Cited by 39
Continuous Delivery of IFN-β Promotes Sustained Maturation of Intratumoral Vasculature
Dickson, P. V., Hamner, J. B., Streck, C. J., Ng, C. Y., McCarville, M. B., Calabrese, C. R., Gilbertson, R. J., Stewart, C. F., Wilson, C., Gaber, M. W., et al. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0259 · Cited by 41
EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
Potikyan, G., Savene, R. O. V., Gaulden, J. M., France, K. A., Zhou, Z., Kleinerman, E. S., Lessnick, S. L., & Denny, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4140 · Cited by 39
Competition for Endothelial Cell Polarity Drives Vascular Morphogenesis
Barbacena, P., Dominguez-Cejudo, M. A., Fonseca, C. G., Gómez‐González, M., Faure, L. M., Zarkada, G., Pena, A., Pezzarossa, A., Ramalho, D., Giarratano, Y., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.09.002 · Cited by 41
Engineered plant extracellular vesicles for natural delivery across physiological barriers
Wang, Y., Wu, Y., Shen, S. Q., Liu, Y., Xia, Y., Xia, H., Xie, Z., & Xu, Y. (2024) · Food & Function · doi:10.1039/d3fo03503d · Cited by 39
Immunomodulation by endothelial cells: prospects for cancer therapy
Alnaqbi, H., Becker, L. M., Mousa, M., Alshamsi, F. Y., Azzam, S. K., Veseli, B. E., Hymel, L. A., Alhosani, K. M., Alhusain, M., Mazzone, M., et al. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.002 · Cited by 41
Liao, C.-Y., Chen, Y., Wu, Y., Chao, H., Chiu, H., Wang, T., Chen, J.-R., Shiao, T., & Lu, C. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00779-4 · Cited by 41
Chatterjee, S., Wieczorek, C. M., Schöttle, J., Siobal, M., Hinze, Y., Franz, T., Florin, A., Adamczak, J. M., Heukamp, L. C., Neumaier, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2986 · Cited by 39
Genetic Diversity of Hepatocellular Carcinomas and its Potential Impact on Targeted Therapies
Zucman‐Rossi, J., & Laurent‐Puig, P. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.997 · Cited by 40
Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis?
Ferreira, V. P., Molina, M. C., Schwaeble, W., David Lemus, A., & Ferreira, A. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.02.005 · Cited by 46
Nerini, I. F., Cesca, M., Bizzaro, F., & Giavazzi, R. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0123-1 · Cited by 40
Masuda, C., Sugimoto, M., Wakita, D., Monnai, M., Ishimaru, C., Nakamura, R., Kinoshita, M., Yorozu, K., Kurasawa, M., Kondoh, O., et al. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-10008-z · Cited by 39
Tumor Endothelial Cell—A Biological Tool for Translational Cancer Research
Annan, D. A., Kikuchi, H., Maishi, N., Hida, Y., & Hida, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093238 · Cited by 38
Management of patients with intermediate stage hepatocellular carcinoma
Prince, D. S., Liu, K., Xu, W., Chen, M., Sun, J., Lu, X., & Ji, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920970840 · Cited by 40
Remodeling tumor microenvironment with nanomedicines
Martin, J. D., Miyazaki, T., & Cabral, H. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1730 · Cited by 42
Cesca, M., Frapolli, R., Berndt, A., Scarlato, V., Richter, P., Kosmehl, H., D’Incalci, M., Ryan, A. J., & Giavazzi, R. (2009) · Neoplasia · doi:10.1593/neo.09866 · Cited by 40
Bow, H., Hwang, L. S., Schildhaus, N., Xing, J., Murray, L., Salditch, Q., Ye, X., Zhang, Y., Weingart, J., Brem, H., et al. (2014) · Journal of Neurosurgery · doi:10.3171/2013.11.jns13556 · Cited by 36
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2002) · Annals of Oncology · doi:10.1093/annonc/mdg033 · Cited by 38
Opportunities and Challenges in Tumor Angiogenesis Research
Li, Q., Bromberg-White, J. L., & Qian, C.-N. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394280-7.00006-3 · Cited by 44
The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†
Reardon, D. A., Desjardins, A., Rich, J. N., & Vredenburgh, J. J. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0052-6 · Cited by 38
Poulsen, H. S., Urup, T. H., Michaelsen, S. R., Staberg, M., Lassen, U., & Villingshøj, M. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39306 · Cited by 44
Tam, Y. T., To, K. K. W., & Chow, A. H. L. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.12.026 · Cited by 37
Nanomedicine‐Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy
Wang, J., Zhang, B., Sun, J., Wang, Y., & Wang, H. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900083 · Cited by 39
Zhang, Z., Wang, Z., Xiong, Y., Wang, C., Deng, Q., Yang, T., Xu, Q., Yong, Z., Yang, X., & Li, Z. (2023) · Biomaterials Science · doi:10.1039/d2bm01691e · Cited by 37
Angiogenesis in malignant melanoma
Felcht, M., & Thomas, M. (2015) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12580 · Cited by 40
Study on Tumor Microvasculature Damage Induced by Alternate Cooling and Heating
Shen, Y., Liu, P., Zhang, A., & Xu, L. X. (2008) · Annals of Biomedical Engineering · doi:10.1007/s10439-008-9511-2 · Cited by 37
Post-Treatment Imaging Changes in Primary Brain Tumors
O'Brien, B. J., & Colen, R. R. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0397-x · Cited by 38
Hipoxia tumoral. Papel del factor inducible por hipoxia
Fraga, A. M., Ribeiro, R. J. T., & Medeiros, R. (2009) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(09)72891-8 · Cited by 54
Cao, M., Liang, Y., Shen, C., Miller, K. D., & Stantz, K. M. (2009) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2008.2012035 · Cited by 41
Zhu, H., Yang, X., Ding, Y., Liu, J., Lü, J., Zhan, L., Qin, Q., Zhang, H., Chen, X., Yang, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep14503 · Cited by 38
Lee, S. M., James, L. E., Büchler, T., Snee, M. P., Ellis, P., & Hackshaw, A. K. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.032 · Cited by 37
The solid tumor microenvironment and related targeting strategies: a concise review
Wang, Y., Zhou, H., Ju, S., Dong, X., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563858 · Cited by 219
Anti‐angiogenic Therapy: Concept to Clinic
Young, R., & Reed, M. (2011) · Microcirculation · doi:10.1111/j.1549-8719.2011.00147.x · Cited by 36
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations
Mulder, K. E., Scarfe, A. G., Chua, N. S., & Spratlin, J. L. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557657 · Cited by 38
Mollard, S., Ciccolini, J., Imbs, D.-C., Cheikh, R. E., Barbolosi, D., & Benzekry, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15484 · Cited by 40
Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target
Javaid, F., Pilotti, C., Camilli, C., Kallenberg, D. M., Bahou, C., Blackburn, J. W. D., Baker, J. R., Greenwood, J., Moss, S. E., & Chudasama, V. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00104c · Cited by 37
The development of tumour vascular networks
Fouladzadeh, A., Dorraki, M., Min, K. K. M., Cockshell, M. P., Thompson, E. J., Verjans, J. W. H., Allison, A., Bonder, C. S., & Abbott, D. (2021) · Communications Biology · doi:10.1038/s42003-021-02632-x · Cited by 36
Hayano, K., Yoshida, H., Zhu, A. X., & Sahani, D. V. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3064-z · Cited by 38
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
Frederick, P. J., Straughn, J. M., Alvarez, R. D., & Buchsbaum, D. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.01.008 · Cited by 36
Practical Vessel Imaging by Computed Tomography in Live Transgenic Mouse Models for Human Tumors
Kindlmann, G., Weinstein, D. M., Jones, G., Johnson, C. R., Capecchi, M. R., & Keller, C. (2005) · Molecular Imaging · doi:10.2310/7290.2005.05166 · Cited by 36
Modeling angiogenesis: A discrete to continuum description
Pillay, S., Byrne, H. M., & Maini, P. K. (2017) · Physical review. E · doi:10.1103/physreve.95.012410 · Cited by 36
Parikh, A. H., Smith, J. K., Ewend, M. G., & Bullitt, E. (2004) · Technology in Cancer Research & Treatment · doi:10.1177/153303460400300608 · Cited by 36
Fenton, B. M., Paoni, S. F., & Ding, I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0434 · Cited by 36
Tumor endothelial markers as a target in cancer
Ribatti, D., Ranieri, G., Basile, A., Azzariti, A., Paradiso, A., & Vacca, A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.725047 · Cited by 36
Taguchi, E., Nakamura, K., Miura, T., Shibuya, M., & Isoe, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00724.x · Cited by 36
Anti-angiogenic drug discovery: lessons from the past and thoughts for the future
Wu, J. M., & Staton, C. A. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.695774 · Cited by 37
Recent advances in tumor vasculature targeting using liposomal drug delivery systems
Lila, A. S. A., Ishida, T., & Kiwada, H. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903289928 · Cited by 38
Liu, Y., Kim, Y. J., Siriwon, N., Rohrs, J. A., Yu, Z., & Wanga, P. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26566 · Cited by 36
Tumour vasculature: Friend or foe of oncolytic viruses?
Santry, L. A., van Vloten, J. P., Knapp, J. P., Matuszewska, K., McAusland, T. M., Minott, J. A., Mould, R. C., Stegelmeier, A. A., Major, P. P., Wootton, S. K., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.007 · Cited by 37
Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies
Majewska, A., Wilkus, K., Brodaczewska, K. K., & Kiéda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020520 · Cited by 37
Daniele, G., Raspagliesi, F., Scambia, G., Pisano, C., Colombo, N., Frezzini, S., Tognon, G., Artioli, G., Gadducci, A., Lauria, R., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002434 · Cited by 38
The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia
Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 37
Enhanced Active Targeting via Cooperative Binding of Ligands on Liposomes to Target Receptors
Sugiyama, T., Asai, T., Nedachi, Y. M., Katanasaka, Y., Shimizu, K., Maeda, N., & Oku, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067550 · Cited by 38
Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network
Zhang, B., Liu, L., Zhao, S., Wang, X., Liu, L., & Li, S. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/278405 · Cited by 35
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 37
Poljak‐Blaži, M., Kolarić, D., Jaganjac, M., Žarković, K., Skala, K., & Žarković, N. (2009) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2009.01.002 · Cited by 35
Bhattacharya, A., Tóth, K., Sen, A., Seshadri, M., Cao, S., Durrani, F. A., Faber, E. B., Repasky, E. A., & Rustum, Y. M. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.025 · Cited by 36
Antiangiogenics and radiotherapy
Shannon, A. M., & Williams, K. J. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.8.0009 · Cited by 35
Hare, J. I., Neijzen, R. W., Anantha, M., Santos, N. D., Harasym, N. L., Webb, M. S., Allen, T. M., Bally, M. B., & Waterhouse, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062349 · Cited by 34
Anaplastic thyroid cancer: a comprehensive review of novel therapy
Kojic, S. L., Strugnell, S. S., & Wiseman, S. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.179 · Cited by 38
Jasinghe, V. J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Palaniyandi, S., Glaser, K. B., Albert, D. H., Davidsen, S. K., & Chen, C.-S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.010 · Cited by 34
In Vivo Application of Proton-Electron Double-Resonance Imaging
Kishimoto, S., Krishna, M. C., Khramtsov, V. V., Utsumi, H., & Lurie, D. J. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7341 · Cited by 34
Metastasis inhibition in breast cancer by targeting cancer cell extravasation
Cominetti, M. R., Altei, W. F., & Selistre-de-Araújo, H. S. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s166725 · Cited by 38
Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies
Stokum, J. A., Gerzanich, V., Sheth, K. N., Kimberly, W. T., & Simard, J. M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023429 · Cited by 36
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking
Zhao, Y., Ting, K. K., Coleman, P. R., Qi, Y., Chen, J., Vadas, M. A., & Gamble, J. R. (2021) · Cancers · doi:10.3390/cancers13071724 · Cited by 36
Natarajan, V., Ha, S., Delgado, A., Jacobson, R. I., Alhalhooly, L., Choi, Y., & Kim, J. (2022) · Cancers · doi:10.3390/cancers14102448 · Cited by 37
Xiao, M., Shi, Y., Jiang, S., Cao, M., Chen, W., Xu, Y. F., Xu, Z., & Wang, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039378 · Cited by 37
Li, W., Guo, M., Liu, Y., Mu, W., Deng, G., Li, C., & Qiu, C. (2015) · Biological Trace Element Research · doi:10.1007/s12011-015-0554-6 · Cited by 37
Lemasson, B., Christen, T., Serduc, R., Maisin, C., Bouchet, A., Duc, G. L., Rémy, C., & Barbier, E. (2012) · Radiology · doi:10.1148/radiol.12112621 · Cited by 34
Verreault, M., Strutt, D., Masin, D., Anantha, M., Waterhouse, D., Yapp, D. T. T., & Bally, M. B. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.095 · Cited by 36
Combining radiotherapy and angiogenesis inhibitors: Clinical trial design
Citrin, D. E., Ménard, C. M., & Camphausen, K. A. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.065 · Cited by 37
Targeted therapy in rectal cancer.
Willett, C. G., Duda, D. G., Czito, B. G., Bendell, J. C., Clark, J. W., & Jain, R. K. (2007) · PubMed · Cited by 40
Self-citationMR Angiography of Tumor-related Vasculature: From the Clinic to the Micro-environment
van Vliet, M., van Dijke, C. F., Wielopolski, P. A., ten Hagen, T. L. M., Veenland, J. F., Preda, A., Loeve, A. J., Eggermont, A. M. M., & Krestin, G. P. (2005) · Radiographics · doi:10.1148/rg.25si055512 · Cited by 34
Tyrrell, J. A., Mahadevan, V. S., Tong, R. T., Brown, E. B., Jain, R. K., & Roysam, B. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.08.005 · Cited by 34
Self-citationRajeshkumar, N. V., Rai, A., & Gulati, A. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9000-3 · Cited by 35
Abbas, M., Ahmed, A., Khan, G. J., Baig, M. M. F. A., Naveed, M., Mikrani, R., Cao, T., Naeem, S., Shi, M., & Dingding, C. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.08.003 · Cited by 33
A Mathematical Dissection of the Adaptation of Cell Populations to Fluctuating Oxygen Levels
Ardaševa, A., Gatenby, R. A., Anderson, A. R. A., Byrne, H. M., Maini, P. K., & Lorenzi, T. (2020) · Bulletin of Mathematical Biology · doi:10.1007/s11538-020-00754-7 · Cited by 38
Wang, N., Gao, Q., Tang, J., Jiang, Y., Yang, L., Shi, X., Chen, Y., Zhang, Y., Fu, S., & Lin, S. (2021) · Drug Delivery · doi:10.1080/10717544.2020.1869864 · Cited by 34
Modeling the Impact of Anticancer Agents on Metastatic Spreading
Benzekry, S., André, N., Benabdallah, A., Ciccolini, J., Faivre, C., Hubert, F., & Barbolosi, D. (2012) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20127114 · Cited by 33
Rolfo, C. D., Raez, L. E., Bronte, G., Santos, E. S., Papadimitriou, K., Buffoni, L., van Meerbeeck, J. P., & Russo, A. D. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.812630 · Cited by 34
Liu, L., Beck, H., Wang, X., Hsieh, H., Mason, R. P., & Liu, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043314 · Cited by 34
Chen, L., Wu, Y., Liu, P., Wang, J., Wang, G., Jin, Q., Zhou, J., & Zhu, J. (2011) · Medical Oncology · doi:10.1007/s12032-010-9690-1 · Cited by 33
Wuthrick, E. J., Kamrava, M. R., Curran, W. J., Werner‐Wasik, M., Camphausen, K. A., Hyslop, T., Axelrod, R. S., Andrews, D. W., Glass, J., Machtay, M. X., et al. (2011) · Cancer · doi:10.1002/cncr.26216 · Cited by 34
Okada, K., Yamasaki, K., Tanaka, C., Fujisaki, H., Osugi, Y., & Hara, J. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt124 · Cited by 33
Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET
Honer, M., Ebenhan, T., ALLEGRINI, P. R., Ametamey, S. M., Becquet, M., Cannet, C., Lane, H. A., O’Reilly, T., Schubiger, P. A., Sticker-Jantscheff, M., et al. (2010) · Translational Oncology · doi:10.1593/tlo.10127 · Cited by 33
Folkman, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_1 · Cited by 36
Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis
Buxton, I. L. O., Yokdang, N., & Matz, R. M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.021 · Cited by 37
Khong, T. L., Larsen, H., Raatz, Y., & Paleolog, E. M. (2007) · Angiogenesis · doi:10.1007/s10456-007-9081-1 · Cited by 37
Brazelle, W., Shi, W., & Siemann, D. W. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.02.023 · Cited by 33
Angiogenesis and Lymphangiogenesis in Tumors: Insights from Intravital MicroscopyPreprint
JAIN, R. K. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.239 · Cited by 34
Self-citationJia, C., Luo, B., Wang, H., Bian, Y., Li, X., Li, S., & Wang, H. (2017) · Advanced Materials · doi:10.1002/adma.201701154 · Cited by 32
Nanotechnology in Cancer Drug Therapy: A Biocomputational Approach
Frieboes, H. B., Sinek, J. P., Nalcioğlu, O., Fruehauf, J. P., & Cristini, V. (2007) · Springer eBooks · doi:10.1007/978-0-387-25842-3_15 · Cited by 36
Perforated Viscus in a Patient with Non-small Cell Lung Cancer Receiving Bevacizumab
Gray, J. E., Murren, J. R., Sharma, A., Kelley, S., Detterbeck, F. C., & Bepler, G. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31805fea51 · Cited by 32
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer
Duda, D. G. (2012) · ISRN Cell Biology · doi:10.5402/2012/587259 · Cited by 38
Targeted trials in ovarian cancer
Ledermann, J. A., & Raja, F. A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.008 · Cited by 33
Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck
Schmitz, S., & Machiels, J. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0412-6 · Cited by 32
Yoon, C., Lee, H.-J., Park, D. J., Lee, Y., Tap, W. D., Eisinger‐Mathason, T. S. K., Hart, C. P., Choy, E., Simon, M. C., & Yoon, S. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.186 · Cited by 31
Verstraete, M., Debucquoy, A., Dekervel, J., van Pelt, J. F., Verslype, C., Devos, E., Chiritescu, G., Dumon, K., D’Hoore, A. J. L., Gevaert, O., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.93 · Cited by 32
Bao, X., Wang, M., Luo, J.-M., Wang, S.-Y., Zhang, Y.-P., & Zhang, Y.-J. (2016) · Theranostics · doi:10.7150/thno.13917 · Cited by 31
Bréchon, M., Dior, M., Dréanic, J., Brieau, B., Guillaumot, M., Brézault, C., Mir, O., Goldwasser, F., & Coriat, R. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0492-6 · Cited by 32
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.